Indian drug, biotech firms weigh pros, cons of U.S. health reform
The health reform bill recently passed by House lawmakers could increase demand for generic drugs and boost the profit of generic drugmakers based in India, industry executives said. However, manufacturers of generic biotech drugs in India would also be adversely affected by a measure that gives brand-name biopharmaceutical firms 12 years of market protection.
Economic Times (India), The
| 11/10
This story published in FDLI SmartBrief on 11/10/2009
Get stories like these delivered daily for FREE:
|
FDLI SmartBrief
Designed specifically for professionals involved in the food and drug law community, FDLI SmartBrief is a FREE daily e-mail newsletter. It provides the latest need-to-know news and industry information that maximizes your time, giving you an edge over your competition. Learn more |
|